Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 May 17;143(2):669–680.e12. doi: 10.1016/j.jaci.2018.05.003

Figure 7. Therapeutic treatment with R321 attenuates established asthmatic lung and airway inflammation in allergen-sensitized/challenged mice.

Figure 7

(A) R321 administered at 12 mg/kg inhibits recruitment of eosinophils to the lung airspaces by 74.18 ± 6.50%. (B) DRA-allergen challenged mice (Vh) develop significant blood eosinophilia as compared to sham-challenged mice (PBS). Treatment with R321 reduces blood eosinophil numbers to levels not significantly different than those observed in allergen sensitized/PBS-sham challenged mice. (C) Following therapeutic treatment with 12 mg/kg of R321, lungs stained for MBP1 positive cells showed tissue eosinophil counts not significantly different from the PBS-sham challenged mice, an 83.30 ± 7.29 % reduction compared to vehicle control. Results are expressed as % MBP1 positive cells compared to total nucleated cells. (D) Surface expression of CCR3 in blood eosinophils is reduced upon allergen challenge. R321 does not inhibit CCR3 internalization, but has a promoting effect (vehicle MFI of 13.7 vs. R321-treated group MFI of 11.7, p=0.01). The mean ± SEM is shown for 5 mice/treatment group. (****p<0.0001, ***p<0.001,**p<0.01, *p <0.05,ns not significant). (E) Representative images of mouse lung airways (top) and blood vessels (bottom) from Fig. 7C immunostained with HRP-conjugated antibodies to MBP1 (positive cells are dark brown). Black bars represent 100 μm.